Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications
Journal
Pharmacological Research
Journal Volume
139
Pages
166-172
Date Issued
2019
Author(s)
Abstract
The aims of this study were to identify types of deficiencies resulting in delay of approvals for drugs eventually approved by the US FDA and to search for factors associated with higher first-cycle approval rates. Review documents of New Drug Applications approved between 2008 and 2017 were retrieved from the Drugs@FDA database. Basic characteristics of the applications, regulatory actions, and reasons for non-approvals and/or major amendments after first review cycle were investigated. Of 825 applications studied, 446 (54.1%) applications received first-cycle approvals without a review extension resulting from a major amendment. Non-approvals (240, 29.1%) were based primarily on chemistry/manufacturing/controls and safety reasons. A higher first-cycle approval rate was associated with factors related to unmet medical needs or innovative development. The association between higher first-cycle approval rates and innovative drugs or those addressing unmet needs reveals the FDA's commitment in advancing innovation and protecting public health. ? 2018
Subjects
First-cycle approval; Product attributes
Other Subjects
anticonvulsive agent; antineoplastic agent; antiparkinson agent; antivirus agent; digestive tract agent; vitamin; Article; chemistry; controlled study; correlational study; drug approval; drug control; drug formulary; drug manufacture; drug safety; food and drug administration; priority journal; United States; drug approval; Food and Drug Administration; statistics and numerical data; Drug Approval; United States; United States Food and Drug Administration
Type
journal article